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Integration of Chronobiological 
Concepts for NSCLC Management
Christian Focan, Anne-Catherine Davin, Maryam Bourhaba 
and Marie-Pascale Graas
Abstract
The authors reviewed pertinent experimental and clinical data allowing to 
consider the interest of taking into account the temporal dimension (‘circadian’) 
for prevention and management of the majority of cancers, i.e., non-small cell 
lung carcinoma (NSCLC). The universal importance of circadian rhythms has 
been acknowledged in animal or human situations regarding carcinogenesis and 
cancer promotion; cell kinetics, apoptosis, molecular genetics, as well as DNA 
repair mechanisms, platinum resistance…; molecular targets (i.e., epidermal 
growth factor reception-EGFR); and all lymphoid and immunology machin-
ery components. Also chronotolerance to all chemotherapeutic agents useful 
for treating human lung cancer has also been evidenced. A few randomized 
clinical chronotherapy trials were performed in human NSCLC. One limited 
trial has shown apparent chronoefficiency, while in another one, chronotoler-
ance to 5-fluorouracil and a platinum derivative were confirmed. The limited 
improvement of outcome in human NSCLC, even through the use of targeted 
and biological therapies (such as tyrosine-kinase (TKI) or vascular-endothelial-
growth-factor (VEGFR) inhibitors; immunotherapy), allows to consider launch-
ing specific trials in human NSCLC aiming at either restoring a normal circadian 
structure of the host or taking into account circadian variations of specific 
targets. By now unfortunately, no targeted or immunotherapy trials have been 
launched considering temporal dimension.
Keywords: circadian rhythms NSCLC review
1. Introduction
1.1 Circadian timing system
Life is structured in space but also in time. Biological rhythms have been 
documented in all processes involved in the malignant transformation of cells as 
well as in the cellular proliferation of both healthy and tumor tissues [1–5]. All 
physiological functions expressed their metabolic or specific activities according 
to a circadian variation [1–5]. This is the case not only for actively dividing tissues 
but also for all other tissues, such as the myocardium, central nervous system, 
or organs involved in the metabolization, detoxification and excretion of drugs 
(kidney, liver) [3–5].
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Recent advances identify critical molecular events that rhythmically control 
drug metabolism and detoxification, cell cycle, molecular targets, deoxyribonucleic 
acid (DNA) repair, apoptosis, and angiogenesis [3–5]. The coordination of these 
processes along the 24-h period is ensured by the circadian timing system (CTS) 
whose hierarchical organization determines chronotherapeutic effects [3–5]. The 
CTS coordinates physiology and cellular functions over a 24-h period (Figures 1 
and 2). This circadian physiology is generated or controlled by a central pacemaker, 
the suprachiasmatic nuclei (SCN) in the hypothalamus. The SCN generate circadian 
physiology through diffusible signals, including transforming growth factor-alpha 
(TGF-alpha), epidermal growth factor (EGF), prokineticin-2, cardiotrophin-like 
cytokine, and neuroanatomic sympathetic and parasympathetic pathways [1–8].
A dozen specific clock genes constitute the core of the molecular clock in mam-
mals [3–6]. These genes are involved in transcriptional and posttranscriptional 
activation and inhibition regulatory loops that result in the generation of the 
circadian oscillation in all physiological systems and individual mammalian cells 
[3–5]. In particular, the circadian locomotor output cycles kaput-brain and muscle 
ARNT-like protein-1 (CLOCK-BMAL1) or NPAS2-BMAL1 protein dimers play a 
key role in the molecular clock through the activation of transcriptional clock genes 
period’s (Per’s), cryptochrome (Cry’s), and Reverb’s [3–5, 9] (Figures 1 and 2).
Proper circadian regulation is essential for the well-being of the organism, 
and disruption of circadian rhythms is associated with pathological conditions 
including cancer [1, 5, 10, 11]. In mammals, the core clock genes, Per1 and Per2, 
are key regulators of circadian rhythms in central clock, in the hypothalamus, and 
in peripheral tissues [9–13]. Recent findings revealed molecular links between Per 
Figure 1. 
Schematic view of the circadian timing system (CTS). The suprachiasmatic nucleus (SCN) is a biological clock 
located at the floor of the hypothalamus. Its period (cycle duration) is calibrated by the alternation of light (L) 
and darkness (D) through the rhythmic melatonin secretion by the pineal gland. The SCN controls or coordinates 
circadian rhythms in the body. Abbreviations: PVN, paraventricular nucleus; NPY, neuropeptide Y; TGF-alpha, 
transforming growth factor α; EGF, epidermal growth factor; Σ, sympathetic (after Levi et al. [3]; adapted).
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genes and cellular components that control fundamental cellular processes such 
as cell division and DNA damage [9–13]. New data also shed light on mechanisms 
by which circadian oscillators operate in peripheral organs to influence tissue-
dependent metabolic and hormonal pathways [4, 5]. Circadian cycles are linked to 
basic cellular functions, as well as to tissue-specific processes through the control 
of gene expression and protein interactions. By controlling global networks such as 
chromatin remolding and protein families, which themselves regulate a broad range 
of cellular functions, circadian regulation impinges upon almost all major physi-
ological pathways including immunological ones [4, 5].
1.2 Aim of this review
In 2002, we performed an overview of accessible experimental and clinical data 
allowing to believe in possible improvement in NSCLC management through chrono-
biological considerations. Here we will update our previous review with experimental 
and clinical recent contributions considering only circadian rhythmicity [14].
It is to be emphasized that we were unable to find any study on that subject 
using new biological alternatives such as targeted therapies or immunotherapy 
approaches.
2. Carcinogenesis
Studies performed by Hashimoto et al. on a murine model with circadian-
varying lung tumor induction through timed single- or split-dose irradiation have 
already been reviewed [14, 15].
Cancer development associated to circadian disturbances both in damaged 
(target) and undamaged tissues and systems [1, 3–5] has been described some years 
Figure 2. 
Schematic representation of the molecular clock and the pathways involved into the control of relevant drug 
metabolism, cell cycle, DNA repair, and apoptosis in mammalian tissues. The protein dimer BMAL1-CLOCK 
or BMAL1-NPAS2 (a CLOCK homolog) plays an essential role in the rhythmic transcription of clock-
controlled genes. After Levi et al. [3]; modified.
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ago. Experimentally, the importance of deregulation of circadian rhythms before 
the development of liver cancer in rats exposed to diethyl-nitrosamine, a carcinogen 
that can also induce lung tumors, was reported by Filipsky et al. [16].
Molecular insights illustrate how dysregulation of circadian rhythms might 
influence the susceptibility to cancer development and provide further support for 
the emerging role of circadian genes in tumor suppression [12]. Silencing of tumor 
suppressor genes, such as the Per1—clock core gene, resulting from epigenetic 
alterations may occur early in lung cancer tumorigenesis [9, 17].
These observations allow considering Per1 gene as a potential target for 
chemoprevention.
Epidemiologic studies in human beings have evidenced a probable relationship 
between altered circadian rhythms and tumorigenesis. A high incidence of cancer 
has been observed in long-term shift workers such as flight attendants, nurses, 
or industrial workers [18–20]. Recent studies have also suggested that alterations 
of sleep quality were susceptible to enhance the risk of various cancers including 
lung cancers [21, 22]. Disruption of melatonin circadian rhythms (peak at night 
after dim-lighting) could partially explain such observations [23]. However, a large 
epidemiologic on thousands of Chinese female textile workers apparently failed to 
confirm an increased risk of lung carcinoma [24].
On the other hand, sport practice and regular physical activity, which are known 
to facilitate and maintain circadian general activities, may have an inverse effect, 
thus minimizing the risk of developing a lung cancer [25].
3. Cell kinetics and molecular biology
3.1 Cell kinetics
Hashimoto et al. recently reported that DNA synthesis activity in the normal 
lung was low but higher during the night [15]. Also a large number of experimental 
animal studies document circadian rhythm in cell proliferation in spontaneous or 
transplanted tumors, growing in ascitic fluid or solid phases [1, 2]. Precisely, Burns 
et al. studied alterations of DNA synthesis rhythmicity in selected organs of mice 
(i.e., bone marrow) bearing a transplanted Lewis lung carcinoma (LLC) [26].
Colombo et al. [27] reported day/night differences of spontaneous apoptosis in 
two different murine tumors, one of these being a lung one, in addition to circadian 
rhythms of division, peaks of apoptosis matching with mitoses valleys [27].
In human, circadian rhythmicity of cell proliferation has been reported for squa-
mous cell carcinomas of the lung, as those of the skin and cervix [1, 2, 14, 28]. Various 
mechanisms responsible for the deregulation of the cell cycle and enhanced suscepti-
bility to oncogenesis through activation of cell proliferation and cancer promotion have 
been identified. For example, in NSCLC, overexpression of cyclin D1, and mutation 
of p16 leading to a shortened and accelerated G1-phase and permanent phosphoryla-
tion (and inactivation) of pRb are known; in addition, mutations of p53 (with further 
impaired apoptosis) or pRb have been observed both in NSCLC and SCLC [29].
3.2 Molecular biology
3.2.1 Clock genes and circadian regulation
Tissues such as the liver, pituitary, and kidney but also the lung exhibit robust 
circadian rhythmicity in cultures [3–5]. Circadian timers are important for lung 
functions; for example, there is a well-documented link between diurnal variations 
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in lung physiology (i.e., airway narrowing and inflammation) and nocturnal 
asthma [30]. Gibbs et al. have studied the cellular localization of core clock genes 
in both mouse and human organotypic lung slices [30]; they also established the 
effects of glucocorticoids on pulmonary clock [30]. They were able to demonstrate 
a marked circadian rhythm in PER2 expression that is responsive to glucocorticoids. 
Immunohistochemical techniques were used to localize specific expression of core 
clock proteins and glucocorticoid receptor on the epithelial cells lining the bron-
chioles (Clara cells and type II pneumocyte cells) in both mouse and human lung 
tissues [30]. Selective ablation of Clara cells resulted in the loss of circadian rhythm 
in lung slices, demonstrating these cells to be critical for maintaining coherent 
circadian oscillations in the lung tissue. The coexpression of glucocorticoid receptor 
and core clock components establishes them as a likely interface between humoral 
suprachiasmatic nucleus output and circadian lung physiology [30].
Clock genes or proteins PER1 and PER2 have been linked to DNA damage response 
pathways in a series of studies, involving among others Lewis lung carcinoma (LLC) 
cells [3, 6, 9, 11–13]. Overexpression of either PER1 or PER2 in cancer cells inhibits 
their neoplastic growth both in vitro and in vivo and increases their apoptotic rate 
[13]. Also high expression of circadian gene mPer2 is able to diminish radiosensitiv-
ity of LLC and EMT6 cells with decreased expression of bax and p53 and increased 
expression of c-myc and bcl-2 [12, 13, 31]. This type of observations illustrates that 
the circadian system is involved in the protection and restoration of tumor cells, i.e., 
those of LC, against environmental detriments, such as gamma irradiation [13]. The 
gene, mPer2, might be considered as an inhibitor of tumor radiotherapy effects [32].
Downregulation of Per1 or Per2 enhanced tumor growth (i.e., of LLC cells) 
in vitro [12, 13, 31, 33]. Thus Per1 and Per2 exert their tumor suppressor functions 
in a circadian time-dependent manner [9, 31–33]. Also downregulation of Per1 
or Per2 increases tumor growth only at given specific times of the day [12]. These 
optimal times may be shifted in tumors that have mutant period genes [12].
Overexpression of Per1 makes human cancer cells sensitive to DNA damage-
included apoptosis; in contrast, inhibition of Per1 in similarly treated cells blunted 
apoptosis [9]. The apoptotic phenotype was associated with altered expression of 
key cell cycle regulators. In addition, Per1 interacted with the checkpoint proteins 
ATM and Chk2. Ectopic expression of Per1 in human NSCLC cell lines led to signifi-
cant growth reduction [6, 9]. Per1 m-RNA expression was high in the normal lung 
and downregulated in a large panel of tumor samples from NSCLC patient samples 
as well as in lung cancer cell lines [3–6, 8, 11]. In addition, Gery et al. showed that 
ectopic or forced expression of Per1 in NSCLC cell lines led to growth inhibition, 
G2M cell cycle arrest, apoptosis, and reduced clonogenic potential [6, 17]. The influ-
ence of Per1 on cell cycle and apoptosis seems to be p53-status independent [5, 13].
Timeless (TIM) a homolog of a drosophila circadian rhythm gene has circadian 
properties in exploration in mammals [34]. Precisely its expression is enhanced in 
lung cancer cell lines where its knockdown was related to the induction of apopto-
sis, suppression of proliferation, and clonogenic growth [34]. In surgically resected 
specimens from 88 consecutive patients, high TIM protein levels as gauged by 
immunohistochemistry (IHC) correlated with poor overall survival [34, 35].
Taken together those results support clearly the hypothesis that circadian 
rhythm disruption plays an important role in lung tumorigenesis, as well as a link 
between circadian epigenetic regulation and cancer development.
3.2.2 Circadian regulation of tumor blood flow and angiogenesis
Hori et al. working on experimental Sato lung tumor were able to correlate 
biological time of greatest tumor growth and highest tissue blood flow (during 
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dark span) [36]. This finding strongly suggests that tumor tissue blood flow has 
a determining influence on tumor proliferative activity and that tumor growth is 
influenced by circadian variation in tumor tissue blood flow [36].
These results were confirmed by Blumenthal et al. who also showed that the 
blood flow rhythm may differ between tumor and normal tissues, thus creating a 
window of opportunity when tumors could be targeted with a therapeutic agent 
such as vascular endothelial growth factor (VEGF) inhibitors [37].
The molecular mechanism regulating circadian expression of VEGF in tumor 
cells (Lewis lung carcinoma cells among others) has been investigated by Koyanagi 
et al. [38]. They found that the expression of VEGF in hypoxic tumor cells was 
affected by the circadian organization of molecular clockwork. The core circadian 
oscillator is composed of an autoregulatory transcription-translation feedback loop 
in which clock and BMAL1 are positive regulators and period (Per) and crypto-
chrome (Cry) genes whose expression in the implanted tumor cells showed also a 
circadian oscillation act as negative ones. The levels of VEGF m-ribonucleic acid 
(RNA) in tumor cells implanted in mice rose substantially in response to hypoxia, 
but the levels fluctuated rhythmically in a circadian fashion. These findings sup-
port the notion that monitoring of circadian rhythm in VEGF production may be 
useful for choosing the most appropriate time of day (i.e., when VEGF production 
is increased) for administrating antiangiogenic agents [38].
In order to identify possible mechanisms underlying tumor progression related 
to circadian disrhythmicity, Yasumina et al. injected epidermoid HeLa cells in nude 
mice exposed to a 24-h light cycle (L/L) or to a “normal” 12-h light/dark cycle (L/D) 
[39]. A significant increase in tumor volume in the L/L group compared with the 
L/D group was observed. In addition, tumor microvessels and stroma were strongly 
increased in L/L mice but were not associated to an increase in the production of 
VEGF. DNA microarray analysis showed enhanced expression of WNT10A (wing-
less gene 10A). WNT10A could stimulate growth of both microvascular endothelial 
cells and fibroblasts in tumors from light-stressed mice, along with marked 
increases in angio-/stromagenesis [39]. Thus, WNT10A may be a novel angio-/
stromagenic growth factor. These findings also suggest that circadian disruption 
induces the progression of malignant tumors via a WNT signaling pathway in 
models involving tumor cells similar to that encountered in human NSCLC [39].
3.2.3  Circadian regulation of epidermal growth factor (EGF) and epidermal 
growth factor receptor (EGFR) pathways
Binding parameters and constant dissociation of EGFR circadian variations, 
peaking late in dark span, were related to DNA synthesis activity variations in 
actively dividing mouse tissues [40]. EGFR by itself was found to be capable 
of phase shifting the prominent circadian rhythm of DNA synthesis, i.e., in 
the esophagus [40, 41]. Phosphorylation of the cyclic monophosphate (cAMP) 
response element-binding protein (CREB) and SER-133-phospho-CREB (PCREB) 
is a transcriptional factor that may regulate circadian cell rhythmicity [41]. 
Concentrations of EGF (and nerve growth factor (NGF)) were monitored in mouse 
saliva [42]; both growth factors exhibited identical diurnal variations, peaking 
between 12:00 and 20:00 h. Otherwise, the effect of EGF injections on cell kinetics 
of mouse tongue epithelium appeared to be time-dependent [41, 42].
Of interest, some studies were also performed in humans. Salivary (on the 
contrary to urinary or plasmatic) EGF level followed an apparent diurnal rhythm 
related to feed [43]. It was markedly reduced in the case of oral inflammation or 
head and neck cancer; in those situations, the capacity of oral mucosal defense 
could therefore be impaired [43].
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EGFR is present in the majority of tumor cells in head and neck cancer [43]. 
Though circadian rhythmicities in cell proliferation and clock genes have been 
demonstrated in oral mucosal [45] and in related cancers [1, 2], so far, no study 
has dealt with the search for circadian variability in EGFR expression in squamous 
cell carcinomas. However, a circadian rhythm in plasmatic EGF level (with an 
acrophase around 14:20, a peak-to-trough interval of 26% and a superimposed 12-h 
frequency) has been reported in metastatic breast cancer patients [45].
As stated earlier, the circadian axis comprises a central clock (SCN; paraventric-
ular areas) and a downstream network of hypothalamic relay station that modulates 
arousal, feeding, and sleeping behavior among others [4, 46] (Figure 2).
Communication between the clock and these hypothalamic signaling centers is 
mediated in part by diffusible substances that include ligands of the EGFR  
[4–8, 44, 46] (Figures 1 and 2). A significant functional role for EGFR in the 
suprachiasmatic nucleus is suggested by recent findings showing that epidermal 
growth factor receptor and its ligand TGF-α are highly expressed in the suprachias-
matic nucleus. Also EGFR activation induces behavioral and physiological effects, 
strengthening the notion that EGFR can modulate suprachiasmatic nucleus neural 
function and behavior [4–8, 44, 46]. Furthermore, Vadigepalli et al. confirmed that 
gene expression response to EGFR is circadian time dependent [8]; this response 
includes several genes encoding different neuropeptide receptors, ion channels, 
and kinases. In order to hypothesize the transcription factors underlying the EGFR 
response, different circadian time-dependent gene expression groups were ana-
lyzed for enriched transcriptional regulatory elements in the promoters. Results 
indicate that several transcription factors such as Elk 1 and cAMP-responsive 
element-binding protein/activating transcription factor family, known to be “input 
points” to the core clock network, are playing a role. Taken together, these results 
indicate that EGFR has a circadian time-dependent neuromodulatory function in 
the suprachiasmatic nucleus [7, 8].
3.2.4 Circadian regulation of immune pathways
Diurnal variation in immune and inflammatory function is evident in the 
physiology and pathology of animals and humans [47, 48].
Studies highlight the extent to which the molecular clock, most notably the core 
clock proteins BMAL1, CLOCK, and REV-ERBα, controls fundamental aspects of 
the immune response [47–49]. Examples include the BMAL1-CLOCK heterodimer-
regulating Toll-like receptor 9 (TLR9) expression and repressing expression of the 
inflammatory monocyte chemokine ligand (CCL2) as well as REV-ERBα suppress-
ing the induction of interleukin-6 (IL-6) [49].
Disruption of the circadian clockwork in macrophages (primary effector 
cells of the innate immune system) by conditional targeting of a key clock gene 
(bmal1) removed all temporal gating of endotoxin-induced cytokine response 
in cultured cells and in vivo. The loss of circadian gating was coincidental with 
suppressed REV-ERBα expression. This work demonstrates that the macrophage 
clockwork provides temporal gating of systemic responses to endotoxin and 
identifies REV-ERBα as the key link between the clock and immune function. 
REV-ERBα may therefore represent a unique therapeutic target in human inflam-
matory disease [49].
Also mechanistically, Bmal1 deficiency in macrophages increases pyruvate kinase 
M2 (PKM2) expression and lactate production, which is required for expression of 
the immune checkpoint protein PD-L1 (programmed cell death-ligand 1) in a STAT1-
dependent manner (signal transducer and activator of transcription 1). Consequently, 
targeted ablation of PKM2 in myeloid cells or administration of anti-PD-L1-neutralizing 
Chronobiology - The Science of Biological Time Structure
8
antibody or supplementation with recombinant interleukin-7 (IL-7) facilitates 
microbial clearance, inhibits T cell apoptosis, reduces multiple organ dysfunction, and 
reduces septic death in Bmal1-deficient mice [47–49].
4.  Chronopharmacology of anticancer drugs active against human 
NSCLC
4.1 Animal data
Circadian variation in pharmacokinetics (PK) has been observed in rodents for all 
the drugs routinely administered to LC patients, i.e., pyrimidine derivatives, anthra-
cyclines, vinca-alkaloïds (vinorelbine), topoisomerase inhibitors, taxanes, platinum 
derivatives, gemcitabine, other antimetabolites, etc. [1, 3–5]. These chrono-PK were 
expressed though circadian-varying metabolization, detoxification, excretion, and 
also maximal concentration (CMax) or area under the curve (AUC) [1, 3–5].
Chronotolerance has been observed in rodent studies long time ago for any 
chemotherapy agents routinely used for NSCLC patients [1–5]. As a recent example, 
best tolerance and chronoefficacy of gemcitabine alone or in combination with 
cisplatin were observed with best antitumor efficacy when both drugs were given 
around their least toxic time schedule, respectively, 11 and 15 hours after light onset 
(HALO) in animal facility [50]. In an older study, Flentje et al. had also documented 
the circadian chronoefficacy of cyclophosphamide (CPA) in LLC [51].
Chronotolerance to an experimental radioimmunotherapy with 131 I-anti-
carcinoembryonic antigen (CEA) IgG was reported [52]. A 30% increase in maxi-
mum tolerated dose was possible when the drug was given at the trough of the bone 
marrow division activity (around 9 HALO) [52].
Clock, as a member of histone acetyltransferases, controls acetylation of histone 
4 required for repair of DNA double-strand breaks thanks to several repair genes 
such as excision repair cross-complementing group 1 (ERCC1) or activator protein 1 
(AP1) [6]. Expression of histone acetyltransferase genes is associated with cisplatin 
resistance [6, 53]. Histone acetyltransferase inhibition (i.e., by vorinostat) may 
increase carboplatin and paclitaxel activity in NSCLC cells [54]. The acetyl-CoA-
binding motive is found in clock and shows sequence similarity with MYST members, 
i.e., Tip 60. Tip 60 which is overexpressed in human epidermoid cisplatin-resistant 
cancer cells [53] exerts a control regulation on several genes implicated in DNA repair 
(i.e., ERCC1 and AP1) [53].
Furthermore, the promoter region of the Tip 60 gene contains several E-boxes, 
and its expression is regulated by the E-box-binding circadian transcription factor 
clock! Thus, clock and Tip 60 regulate not only transcription but also DNA repair, 
through periodic (diurnal) histone acetylation in cell populations that can be found 
in human NSCLC [53].
Finally, of interest, diurnal-varying pharmacokinetics of erlotinib (a largely 
used tyrosine kinase inhibitor (TKI) for treating human NSCLC) has been reported 
both in xenograft-bearing nude mice [55] and in Lewis tumor-bearing mice. 
[56]. Circadian rhythm plays a critical role in the pharmacokinetics of erlotinib 
in mice, and the mechanisms may be attributed to gene expression rhythms of 
drug-metabolizing enzymes in liver tissues [56]. The inhibitory effect of erlotinib 
on phosphorylation of EGFR, AKT (type of serine/threonine protein kinase, also 
called protein kinase B), and mitogen-activated protein kinase (MAPK) varies with 
its administration time. The results indicate that the antitumor effect of erlotinib 
is more potent when the drug is administered when the activities of EGFR and its 
downstream factors increase [55, 56].
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5. Human beings
In human as well, pharmacokinetics of some major drugs used in NSCLC have 
been reported to be circadian varying [1–5, 28, 44]. Circadian variation of plasma 
5-fluorouracil (5 FU) concentration has been repeatedly observed when the 
drug is infused for a few days at a constant rate [57, 58]. This was reported when 
the drug was given either as a single agent or with a platinum derivative [58]. 
Similarly, plasmatic concentration of vindesine, a semisynthetic vinca-alkaloïd 
derived from vinblastine, exhibit circadian variation with peak between 9 am and 
3 pm, when infused at a constant rate for 48 h [59]. Also the fixation of platinum 
ion to plasma proteins was shown to be circadian varying with an acrophase 
during late afternoon [60]. More recent assessment of circadian variability of 
cisplatin pharmacokinetics confirmed that cisplatin clearance was 1.38- and 1. 
22-fold higher for total and unbound drug with administration at 06:00 pm vs. 
06:00 am [61].
Host chronotolerance to anticancer drugs used in NSCLC patients has also 
been observed in clinical practice. Pyrimidine derivatives such as 5 FU are less 
toxic when infused during nighttime sleep [1, 3–5, 57, 58]. Also platinum deriva-
tives such as cisplatin, carboplatin, and oxaliplatin are better tolerated between 
3 and 6 pm while anthracyclines are less toxic in the morning [1, 3–5, 57, 58]. 
The first reported chronotherapy randomized trial, based on diurnal cell kinet-
ics, treating mostly NSCLC patients, compared a 40-h sequential chemotherapy 
beginning either at 10 am or at 10 pm [28]. In this study, patients who received 
the sequential chronotherapy from 10 am experienced significantly greater 
granulocyte toxicity [14, 28].
Focan et al. also reported on host chronotolerance of 124 chemotherapy-naïve 
advanced NSCLC patients, receiving randomly etoposide for 3 days either at 6 am 
Figure 3. 
Programs of ambulatory chronotherapy with 5 FU, folinic acid (leucovorin-LV), and carboplatin (CBDCA). 
The reference schedule is compared to two others with varying peaks (−8 h; +8 h). Daily delivery is 
automatically repeated by a chrono-programmable pump (Melodie) five times every 21 days (FFC5_16).
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(group A) or 6 pm (group B) and cisplatin at day 4 at 6 pm [62]. A lesser degree of 
hematological toxicity was documented in group A, while cisplatin was better toler-
ated in group B [62]. Similar results were reported by Krakowski et al. [63].
Focan et al. also performed a randomized phase I–II trial comparing as first-line 
treatment, a complex sequential chronotherapy with 5 FU, folinic acid (FOL), and car-
boplatin with 24-h sinusoidal variation of drug delivery [64] (Figure 3). The reference 
schedule (peaks of 5 FU and FOL at 4 am, peak of carboplatin at 4 pm vs. two other 
schedules peaking, respectively, at + or – 8 hours, repetition for 5 days every 3 weeks) 
appeared to be the least toxic one with an overall excellent clinical tolerance [14, 64] 
(Figure 4). Toxicity data were reviewed in order to detect a possible gender effect as 
had been observed in metastatic colorectal cancer [3–5, 65]. Despite of no significant 
difference in treatment adaptation or dose intensity between men and women, overall 
increased serious toxicities were recorded in women versus men. Severe leukopenia 
and mucositis occurred more than twice as frequently in women than in men (grade 
3–4 leukopenia per course, 7.7 vs. 3.2%; grade 3–4 mucositis, 6.6 vs. 1.2%) [14].
According to the results of the phase I–II trial described above [64], a phase II 
study was further performed on 68 advanced NSCLC previously untreated patients 
Table 1. 
Gender effect in NSCLC.
Figure 4. 
Tolerability of chronomodulated 5 FU-LV-CBDCA infusion (grades 3–4 toxicities; in green, leucocytes; in red, 
granulocytes; in yellow, mucositis). Reference schedule was clearly the least toxic one (p < 0.007–0.025).
11
Integration of Chronobiological Concepts for NSCLC Management
DOI: http://dx.doi.org/10.5772/intechopen.85710
with the best circadian schedule [3, 14]. An excellent therapeutic index with a 
maximum of 17%, grades II–IV toxicities were observed and a gender effect was 
confirmed (Table 1) [3, 14].
Further analyses in advanced colorectal cancers have shown that the pattern of chro-
notolerance in men was rather sinusoidal with an optimal time corresponding to the ref-
erence modality; conversely in women the pattern was damped with optimal peaks of 
delivery possibly located 6 h later than in men [66]. The male subgroup showed a mean 
clearance (CL) value twice larger than the value observed in the female subgroup [66]. 
On the other hand, one has also to remind that the distribution of genes with circadian-
varying expression was quite different in men and women in oral mucosa [44].
6. Circadian biological and behavioral determinants in LC patients
6.1 Hormones, immune functions, and tumor markers
A number of groups studied tumor-marker (CEA-carcinoembryonic antigen, 
alpha-fetoprotein, and others) rhythms but with similar disappointing results  
[1, 2, 67]. If in controls, a clear group circadian rhythmicity with an afternoon peak 
around 03:00 pm was evident, in cancer patients, individual variability or absence 
of rhythm were evidenced [1, 67].
Hormonal, hematological, and rest-activity cycles perhaps might constitute 
more promising markers of the host’s internal circadian time structure. The most 
prominent hormonal circadian rhythms are cortisol (peak time occurs early in the 
morning in diurnally active persons) and melatonin (peak time occurs during the 
first half of the dark period in diurnally active people) [3–5, 67]. Important altera-
tions of the normal circadian profile of these rhythms have been described in lung 
and other cancer patients with low performance status and high tumor burden [67].
Bartsch and colleagues [68] reported peculiarities in the cortisol and melatonin 
circadian rhythms in LC patients. Experimental data suggest interactions between 
interleukin-2 (IL-2; antitumor immune response is an IL-2-dependent phenomenon) 
and the pineal gland, which also may play a role in the control of immunity and cancer 
growth [69, 70]. The melatonin rhythm was evaluated in a group of LC patients receiv-
ing subcutaneous IL-2 treatment [70]. Prior to IL-2 therapy, none of the patients showed 
a normal 24-h rhythm of melatonin; IL-2 administration induced a normalization of the 
melatonin circadian rhythm with a nighttime peak in the majority of cases [70]. This 
observation suggests that abnormal pineal function in some lung cancer patients might 
arise in part from altered endogenous IL-2 production [70]. On the other hand, IL-2 
administration induced a rise in cortisol with maintenance of 24-h rhythmicity [70].
Melatonin, tryptophan, and 6-sulfatoxymelatonin circadian profiles in blood and 
urine were compared in 30 advanced NSCLC cancer versus 63 healthy volunteers 
[66, 71]. All three molecule concentrations were significantly lower in cancer patients 
with a significant inverse correlation between melatonin and tryptophan levels [71].
Circadian rhythmicity in growth hormone (GH) and insulin-like growth factor-1 
(IGF-1) was studied in control subjects and LC patients [72]. GH stimulates IGF-1 
production in the liver and other tissues, while IGF-1 can promote cell cycle pro-
gression and apoptosis inhibition. GH and IGF-1 also stimulate lymphopoiesis and 
immune function [72, 73].
In LC patients, a progressive increase in GH and a steady decline of IGF-1 
serum levels with loss of circadian rhythmicity were observed. This loss of diurnal 
rhythms could play a role in carcinogenesis and tumor growth regulation [71–75]. 
All profiles of time-related neuroendocrine-immune system components seemed to 
be the advancing stage of disease [71–76].
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Mazzocoli et al. assessed altered time neuroendocrine-immune system func-
tion in lung cancer patients [75]. Circadian rhythmicity with night acrophases was 
validated in the control group for hormone serum level (melatonin, TRH, TSH, 
GH,) and for lymphocyte subset variation (CD3-, CD4-, HLA DR-, CD20-, and 
CD25-expressing cells). Cortisol, CD6, CD8 bright, CD8 dim, CD16, TcR-delta-1, 
and delta-TcS1 presented circadian rhythmicity with acrophase in the morning/at 
noon. In LC patients cortisol, TRH, TSH, and GH serum level and all lymphocyte 
subsets (except for CD4) showed some altered circadian rhythmicity. Mesor of cor-
tisol, TRH, GH, IL-2, and CD16 was increased, whereas that of TSH, IGF-1, CD8, 
CD8 bright, TcR-delta-1, and delta-TcS1 was decreased [75]. Peak times however 
are related similar to those of control subjects [75]. The melatonin/cortisol mean 
nocturnal level ratio was also decreased in LC patients [75, 76]. Taken together, 
these results suggested that lung cancer is associated with alteration in the propor-
tions and 24-h profiles of various lymphocyte subsets; this may be related to disease 
stage and probably altered immune function [73–75, 76].
Lissoni et al. also observed in NSCLC treated by chemotherapy (+/− melatonin) that 
lymphopenia and altered cortisol rhythmicity were associated with worsened quality of 
life (QOL), loss of psychosexual identity, and lower spiritual and faith scores [77, 78].
6.2 Host marker rhythms
The persistence of a circadian time structure like that of control normal subjects 
seems to be an independent prognostic factor, at least in advanced breast or colon 
cancers [10, 18, 79, 80]. As stated earlier, the strongest circadian rhythms are those 
of cortisol (with the clinical interest being the morning-afternoon gradient) and 
melatonin (with a nighttime peak) [2, 4]. Noninvasive easy-to-repeat assessment 
techniques have been validated for the determination of the 24-h time structure: 
titrations of cortisol and melatonin in the saliva and 6-hydroxymelatonin sulfate 
in the urine [81]. Nocturnal urinary 6-sulfatoxymelatonin is also correlated with 
the proliferation of cell nuclear antigen (PCNA) in lung tumors [68]. Thus, its 
determination might constitute a noninvasive tool to estimate circadian tumor cell 
proliferation in lung or other tissues.
Cortisol diurnal rhythm and slope have been related to survival in metastatic 
breast cancer patients by Sephton et al. [18]. Similarly, the same authors together 
with Chinese counterparts could also link the quality of persistent diurnal cortisol 
rhythm to the prognosis (survival) in LC patients [19, 20].
Assessment of the rest-activity circadian cycle by actometry measurements also 
seems an easy way to estimate the general circadian profile of individuals  
[1, 4, 5, 82–84]. In advanced colorectal cancer, it was demonstrated in two studies 
that patients retaining a prominent rest-activity circadian rhythm will enjoy better 
quality of life and sleep, less fatigue, less depression, and improved survival [82–84]. 
Such evaluations were proposed to lung cancer patients and validated [82–84]. Focan 
et al. evaluated rest-activity rhythms in 28 advanced NSCLC before chronotherapy 
[83]. Better general physical activity and circadian rhythmicity were recorded in 
those patients receiving also corticosteroids [83]. Hrushesky and his group also stud-
ied circadian function in NSCLC patients by actigraphic recordings [82, 84]. They 
tried to correlate the rest-activity rhythms with sleep disturbances, quality of life 
(European Organization for Research and Treatment of Cancer (EORTC) Quality of 
Life Questionnaire (QLQ-C30)) and mood (anxiety; depression—HADS—hospital 
anxiety and depression scale) [82, 84]. All patients suffered from severe distur-
bances of daily sleep-activity cycles, but each patient also maintained some degree of 
circadian organization. QOL measurements were correlated with circadian destruc-
tors, fatigue prominent during daytime, and altered moods [82, 84].
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Before initiation of their radiotherapy, a high percentage (30–50%) of 185 
patients experienced significant disturbances in sleep-wake circadian rhythmicity; 
these perturbations occurred in both sleep initiation and maintenance [85].
Recent clinical observations have shown that elevated levels of TGF-alpha 
are associated with fatigue, flattened circadian rhythms, loss of appetite, and 
depression in patients with metastatic cancer [46]. These data support the 
hypothesis that a symptom cluster of fatigue, appetite loss, and sleep disruption 
commonly seen in cancer patients may be related to EGFR ligands released either 
by the cancer itself or by the host in response to the stress of cancer and suggest 
that further examination of their role in the production of symptom clustering 
is warranted [46]. Those observations also suggest to consider the central clock 
as a possible target for restoration of normal circadian rhythmicity in cancer 
patients!
7. Clinical trials
7.1 General considerations
During the last decade, the management of NSCLC has evolved [86–97]. 
Platinum-based chemotherapy remains the standard front-line in treatment of 
advanced unresectable NSCLC in which cisplatin or carboplatin are combined 
with another chemotherapeutic agent such as taxanes, pemetrexed, or gemcitabine 
[87]. However the results in terms of response rate, progression-free survival, and 
median overall survival remained stable over time [86–97].
Thus, progresses confirmed by phase III trials came from targeted and immuno-
therapeutic biological approaches. Targeted therapies against EGFR mutations and 
anaplastic lymphoma kinase (ALK) gene rearrangement have improved the survival 
in a small proportion of patients whose tumors were expressing these molecular 
abnormalities [88–91].
Also the recent development and success of immune checkpoint inhibition of 
programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cyto-
toxic T-lymphocyte antigen-4 (CTLA-4) for treating metastatic cancers seemed to 
open a new pavement for fruitful research [86, 92–97].
Unfortunately to the best of our knowledge, despite precise theoretical obser-
vations depicted related to circadian expression, on targets of TKI inhibitors, 
EGFR blockers, antiangiogenic agents, and immune active-agents (lymphoid 
system; PD1; PDL1), by now no study has been launched to take into account any 
chronobiological considerations!
8. Chemotherapy
As a matter of fact, in NSCLC, only a few studies deal with considerations on 
temporal dimension for drug delivery.
Studies from Focan et al. have already been mentioned and reviewed elsewhere 
[14]. In the first pioneered study [14, 28], a significant better tumor outcome was 
observed in the group treated at the better dosing time, thus from 10 am for a 40-h 
sequential schedule [14]. In the second phase III trial using etoposide and cisplatin, 
despite varying toxicities, there were no differences in overall drug dose intensities 
nor in tumor outcome gauged by the frequency of tumor responses as well as sur-
vival [62]. On the contrary, Krakowski et al. observed an increased dose intensity of 
drugs when given at their best circadian schedule [63].
Chronobiology - The Science of Biological Time Structure
14
According to the results of the phase I-II trial described [59] that had confirmed 
diurnal tolerance of a complex infusion regimen including 5FU, Fol, and carbopla-
tin for 5 days every 3 weeks, a phase II study was further performed on 68 advanced 
NSCLC previously untreated patients with the best circadian schedule [3, 14]. 
Tumor evolution remained within the frame of the literature, but patients enjoyed 
an improved therapeutic index [3, 14].
Lissoni et al. successively performed small randomized trials (with 20–40 
patients per group) in advanced NSCLC patients [67, 68, 77, 78]. They observed 
progressive improvement of tumor outcome (response rate; 1-year survival, etc.) 
and quality of life through the association with standard cisplatin-based chemo-
therapy, melatonin, and sometimes interleukin-2 (IL2) [67, 68, 77, 78]. They have 
reviewed their results on 370 cases suffering from NSCL and gastrointestinal tract 
cancers [78]. They confirmed a higher rate of tumor responses and better long-term 
survival in patients who had received melatonin [78]. These observations were 
linked to positive circadian effects in cancer-relevant psycho-neuroendocrine and 
immune pathways [77, 78]. According to these authors, a high degree of faith may 
positively influence the efficacy of chemotherapy and the clinical evolution of 
NSCLC by improving the lymphocyte-mediated antitumor immune response and 
probably general host circadian rhythmicity [78].
Hrushesky’s group performed also a randomized blinded trial on 84 advanced 
NSCLC patients receiving chemotherapy with etoposide and cisplatin together with 
melatonin or placebo (personal communication). Those patients receiving mela-
tonin during the evening enjoyed higher response rates (29 vs. 8–11%) and longer 
survival in multivariate analysis (personal communication).
Two meta-analyses appeared to confirm survival benefits associated with 
melatonin therapy in cancer patients [98, 99]. One analysis has focused upon 8 trials 
that used a dosage of 20 mg of melatonin, while the second one reviewed 21 clini-
cal trials on solid tumors using various doses of melatonin [98, 99]. Both analyses 
report that the administration of melatonin reduces the relative risk of death at 
1 year by an average of 37%, doubles the frequency of complete response, and 
reduces the prevalence and/or severity of chemotherapy-induced nausea/vomiting, 
hypotension, and hematological toxicity. Thus some authors consider melatonin as 
a probable effective treatment for human NSCLC [100]!
9. Targeted treatments
Despite advances in research and a better understanding of the molecular pathways 
of NSCLC, few effective therapeutic options are available for most patients with NSCLC 
without druggable targets, especially for patients with squamous cell NSCLC [86–91].
Chrono-PKs of erlotinib have been investigated in rodents [55, 56]. On the other 
hand, Iurisci et al. observed an improvement of circadian rest-activity rhythms 
together with a relief of symptoms in a limited trial on advanced NSCLC patients [101].
Nevertheless, no trial taking into account temporal dimension has been 
launched at present time.
10. Immunotherapy
Immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyte antigen-4 
or anti-programmed death 1 (PD-1) or programmed death-ligand 1 (PD-L1) have 
induced durable response rates across a broad range of solid tumors. In NSCLC, 
pembrolizumab and similar antibodies have replaced chemotherapy as first-line 
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treatment for patients with PD-L1 tumor proportion score (TPS) of at least 50% 
[92–97], while pembrolizumab plus platinum and pemetrexed for those with 
nonsquamous histology irrespective of PD-L1 expression [92–97].
As discussed in previous chapters, it is conceivable to consider the temporal 
(diurnal) dimension when administering either targeted or immunologic treat-
ments to lung cancer patients, but, to the best of our knowledge, no study on that 
subject has been launched to date. We could regret this lack of interest, while 
dissection of molecular pathways of the circadian clock system has been awarded in 
2017 with a Nobel Prize!
11. Radiotherapy
In a single non-randomized limited study, gamma knife radiosurgery for brain 
metastases of NSCLC was delivered either in the morning (10.00 am to 12:30 pm, 
58 cases) or in the afternoon (12:30 pm to 3:00 pm, 39 cases) [102]. Patients treated 
in the morning enjoyed better tumor local control at 3 months (97 vs. 67%), longer 
survival (9.5 months vs. 5 months), and a lower rate of central nervous system 
(CNS)-related cause of death. Those results, which may be related to circadian 
susceptibility of target cancer cells (? more cells in G2-M phase; more apoptosis in 
the morning?), prompted the activation of a prospective randomized RTOG study 
whose results have not yet been published.
With another methodology, Badiyan et al. [103] reevaluated the impact of 
daytime on tumor outcomes after stereotactic radiosurgery (SRS), in 437 patients 
NSCLC treated for CNS metastases. They confirmed a cut point of 11:41 am for 
providing the highest predictive value for overall survival [103].
12. Conclusions
In this review, we have tried to gather pertinent animal and human data sup-
porting the need to take into account temporal dimensions (i.e., circadian) for 
prevention and treatment of human NSCLC. The importance of biological rhyth-
micity was evidenced regarding carcinogenesis, molecular biology and genetics, 
cells kinetics, apoptosis, DNA repair mechanisms, platinum resistance, etc. These 
observations are fully applicable to human NSCLC.
Some randomized clinical trials for human LC have confirmed chronotolerance 
and probably chronoefficacy of combined chemotherapy. Furthermore, theoretical 
considerations allow to propose the application of chronobiological concepts to 
improve the management of human NSCLC either by working on the host circadian 
rhythmicity and on circadian variation of targets expression, such EGFR and VEGF 
receptors, or on the new molecular targets or pathways also circadian varying in 
their expression (e.g., ERCC1, DNA repair, Tip 60, etc.).
Similarly circadian variations in multiple immunological pathways warrant 
further interest. These considerations would bring hope to improve overall tumor 
outcome by optimizing “classical” therapeutic index of chemotherapies but also 
circadian host rhythmicity by acting on the central clock (i.e., by TKI administra-
tion) and/or molecular machinery (receptors, various enzymatic pathways, DNA 
metabolism and repair, immunology pathways, etc.).
Also the potential role of melatonin as resynchronizing agent and as a potentially 
active agent warrants further evaluations.
Eventually the increased toxicity of chemotherapy in women is intriguing, 
peculiarly when host circadian rhythmicity seemed to be implicated.
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